欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Leriglitazone_146062-44-4_产品详情
146062-44-4
  • names:

    Leriglitazone

  • CAS号:

    146062-44-4

    MDL Number:
  • MF(分子式): C19H20N2O4S MW(分子量): 372.44
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Leriglitazone
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002657-250mg 250mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM002657-100mg 100mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 146062-44-4
Inchi
InchiKey
分子式 Formula C19H20N2O4S
分子量 Molecular Weight 372.44
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
Leriglitazone(CAS:146062-44-4)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Leriglitazone (Hydroxypioglitazone),吡格列酮的代谢产物
IntroductionLeriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) PioOH is aPPARγagonist, stabilizes the PPARγ activation function (AF) coctivator binding surface and enhances coctivator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) binds to the PPARγ Cerminal ligandinding domain (LBD) withKiof 1.2 μM,induces transcriptional efficacy of the PPARγ (LBD) withEC50of 680 nM.
Application1
Application2
Application3
Leriglitazone (Hydroxypioglitazone),吡格列酮的代谢产物。 Leriglitazone (Hydroxypioglitazone) 为PPARγ激动剂,通过稳定 PPARγ (AF-2) 共激活剂结合表面和增强共激活剂结合能力,提供高转录效力。 Leriglitazone(Hydroxypioglitazone) 与 PPARγC (LBD) 结合,其Ki值为 1.2 μM,诱导 PPARγ (LBD) 转录效率,EC50为 680 nM。Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) PioOH is aPPARγagonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) withKiof 1.2 μM,induces transcriptional efficacy of the PPARγ (LBD) withEC50of 680 nM[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Mosure SA,et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents